Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
40.70
+0.26 (0.64%)
At close: Aug 10, 2026, 4:00 PM EDT
37.48
-3.22 (-7.91%)
Pre-market: Aug 11, 2026, 4:18 AM EDT
Harrow Revenue
Harrow had revenue of $70.66M in the quarter ending June 30, 2026, with 10.85% growth. This brings the company's revenue in the last twelve months to $275.59M, up 21.05% year-over-year. In the year 2025, Harrow had annual revenue of $272.30M with 36.41% growth.
Revenue (ttm)
$275.59M
Revenue Growth
+21.05%
P/S Ratio
5.50
Revenue / Employee
$738,858
Employees
373
Market Cap
1.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 272.30M | 72.69M | 36.41% |
| Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
| Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
| Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
| Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
| Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
| Dec 31, 2019 | 51.17M | 9.79M | 23.67% |
| Dec 31, 2018 | 41.37M | 14.60M | 54.52% |
| Dec 31, 2017 | 26.77M | 6.83M | 34.26% |
| Dec 31, 2016 | 19.94M | 10.23M | 105.25% |
| Dec 31, 2015 | 9.72M | 8.06M | 485.30% |
| Dec 31, 2014 | 1.66M | -8.34M | -83.40% |
| Dec 31, 2013 | 10.00M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.85B |
| Perrigo Company | 4.14B |
| Phibro Animal Health | 1.50B |
| Trulieve Cannabis | 1.14B |
| ANI Pharmaceuticals | 978.38M |
| Pacira BioSciences | 746.16M |
| Alvotech | 562.04M |
| HUTCHMED (China) | 549.12M |
HROW News
- Just now - Harrow Earnings release: Q2 2026 - Filings
- Just now - Harrow Quarterly report: Q2 2026 - Filings
- Just now - Harrow Slides: Q2 2026 - Filings
- 11 hours ago - Harrow reports Q2 EPS (46c), consensus (24c) - TheFly
- 4 days ago - Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M - TheFly
- 4 days ago - Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease - GlobeNewsWire
- 14 days ago - Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 - GlobeNewsWire
- 21 days ago - Harrow and Samsung Bioepis present interim BYOOVIZ post-marketing data - TheFly